NYSE:BMYPharmaceuticals
A Look At Bristol Myers Squibb (BMY) Valuation After US Tariff Threats Hit Pharma Stocks
Reports that the US may apply tariffs of up to 100% on certain imported branded drugs have put regulatory risk front and center for Bristol-Myers Squibb (BMY), prompting investors to reassess the stock.
See our latest analysis for Bristol-Myers Squibb.
After the tariff headlines and the recent ex dividend adjustment, Bristol Myers Squibb’s 1 day share price return of 3.45% contrasts with a 90 day share price return of 12.33% and a 1 year total shareholder return of 13.16%. This suggests...